After a year marked by difficult discussions on the PLFSS 2023, AGIPHARM hopes for a quality dialogue between all the players, both public and private, which will enable us to address the issues of access to treatment in a constructive manner and to devise solutions together that meet the needs.

Access to innovation, assessment of the PLFSS, lessons learned from the health crisis, reindustrialization, image of the pharmaceutical industry... Corinne Blachier-Poisson, General Manager of Amgen France and President of AGIPHARM, gives an overview of the pharmaceutical sector news in her interview in the 3rd issue of Prescription Santé le Mag.

A few days before the PLFSS 2023 begins to be examined in the National Assembly, AGIPHARM is alerting on a text that provides for regulation disconnected from the reality of the drug industry and its innovation dynamics.

A few days after the final adoption of the PLFSS and the passage before the Constitutional Council, AGIPHARM welcomes a text carrying encouraging signals to improve patient access to innovation, consistent with the ambitions formulated by President Macron at the last CSIS, despite a drug budget still underestimated.

Corinne Blachier-Poisson, Managing Director of Amgen France, succeeds Pierre-Claude Fumoleau, former French President of AbbVie, as President of Agipharm for a one-year term.

For her mandate, and in the continuity of AGIPHARM's missions, Corinne Blachier-Poisson will strive to promote innovation in health and ensure that American Pharmaceutical companies located in France are a source of proposals to make our country and of Europe a land of excellence.

The Social Security Financing Bill (PLFSS) for 2021, which is due back for a new reading in the National Assembly on Monday, is the concrete expression of an ambitious reform of early access to innovative drugs that AGIPHARM has long been calling for. 

The implementation of this reform will be crucial if the new system is to deliver on its promises for the benefit of patients.

In the wake of the Economic Recovery Plan, the government and the President of the Republic have called for a reform of the ATU system. Pierre-Claude Fumoleau, President of AbbVie France and of Agipharm, the association of innovative American pharmaceutical companies in France, welcomes this step forward for patients suffering from serious diseases and for innovation in France.

“The response to the Covid-19 crisis cannot be reduced to a proliferation of health nationalisms. On the contrary, it must be based on the pooling of intelligence and skills ”

In the context of the Covid-19 crisis, more and more voices are being raised to restore health independence in France and Europe, highlighting the need to prevent drug shortages and to revive the national territory's attractiveness.

However, positions on this subject often limit the concept of "health independence" to the relocation of production alone, while it involves many other concepts, both crucial and strategic. Moreover, this vision exposes France to a number of risks such as retaliatory measures that could encourage the emergence of drug shortages. 

Therefore, AGIPHARM defines health independence more as the ability of a state to guarantee patients effective and secure access to health products and presents its proposals to achieve this goal.

Pierre-claude Fumoleau, president of the French subsidiary of AbbVie, has been elected president of AGIPHARM. He succeeds Michel Joly, President of Gilead France. Under the aegis of its new president, AGIPHARM will continue its work in close association with Leem, of which it is a member, but also with all decision-makers and actors in the health system to advance three major priorities: '' patient access to drugs, in particular by reviewing the conditions for early access to therapeutic innovation, modernizing the drug evaluation system to adapt it to the new challenges of therapeutic innovation, and finally recreating the conditions for growth for companies in the sector, in order to support investment in tomorrow's treatments, on French territory, and for the provision of new therapeutic solutions to patients.

Cancers, hepatitis, autoimmune or rare diseases… Why do French patients later have access to therapeutic innovations? In this forum, the "ACCèS +" collective, made up of health professionals, patient associations and players in the health industries, calls out to the public authorities and proposes solutions.